Company / Capital Expenditures
Astria Therapeutics, Inc. Capital Expenditures History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$325.0K
FY2024
5-year range
$21.0K / $325.0K
FY2020-FY2024
Trend
+1200.0%
vs FY2023
Sector context
#147 of 194
Health Care
What the data says
Capital Expenditures changed +1200% YoY in FY2024, a notable deviation from the 8-year average annual change of +180%.
Based on SEC 10-K filings.
$325,000 in FY2024 with a 5-year CAGR of +93.4%.
Improved from $91,000 to $325,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +149.2%
- 5-Year CAGR
- +93.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 194This company $325.0K Sector average $117.5M
▼
-99.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +93.4%, indicating consistent growth.
- In FY2024, capital expenditures increased 1200.0% year-over-year.
- Ranks #147 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $325.0K | +1200.0% |
| FY2023 | $25.0K | -72.5% |
| FY2022 | $91.0K | +333.3% |
| FY2021 | $21.0K | -36.4% |
| FY2020 | $33.0K | +175.0% |
| FY2019 | $12.0K | - |
| FY2018 | - | - |
| FY2017 | $57.0K | -87.6% |
| FY2016 | $459.0K | +9.0% |
| FY2015 | $421.0K | +84.6% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026